Whole Exome-seq profiles of prostate cancer cell lines for copy number and PARADIGM analysis

Genomic studies using paired enzalutamide-sensitive and resistant cell models were performed. After transcriptional and copy number profiling, we used PARADIGM to compare the genomic alterations between the parental V16D and resistant MR49F cell models to identify critically deregulated networks to demonstrate the utility of integrative genomic analysis for therapy selection. There were 607 genes and pathway entities that had PARADIGM scores that fell outside the normally distributed range in the MR49F cell line. The top 64 genes were selected for RNAi validation. The most biologically relevant genes between the V16D and MR49F cell line models under enzalutamide treatment conditions were identified as significant by siRNA analysis and deemed biologically relelvant by network and enrichment analyses. Whole Exome-seq profiles of prostate cancer cell lines for copy number analysis